ClinicalTrials.gg
TerminatedNCT04990219Updated Feb 3, 2023

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

A Phase 1 interventional study of Lu AG06466 and Placebo in Multiple Sclerosis, sponsored by H. Lundbeck A/S. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-03.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated for strategic reasons

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
513th of 879
37 · median 50
Started
2021
with 80 others
Phase 1
105 of 1,192
18 open now
Registered
889th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 513th largest by enrollment of the 879 interventional ones that give a count, is one of 81 that started in 2021, is one of 105 in phase 1, and was the 889th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).

Read the detailed description

The participants will be randomized to Lu AG06466 or placebo in a 2:1 ratio.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant has a diagnosis of MS, as per the 2017 McDonald criteria.
  • The participant has clinically stable MS (such as no relapse and/or stable Expanded Disability Status Scale [EDSS] or alternative clinical assessment score) for at least 6 months prior to screening.
  • The participant has ongoing spasticity for at least 90 days prior to screening.
  • The participant is on a stable regimen for at least 30 days prior to screening for all medications and non pharmacological therapies, including therapies that are intended to alleviate spasticity (for example, oral baclofen, tizanidine, dalfampridine), and willing to remain on the same regimen throughout the duration of the study.
  • The participant reports walking impairment due to lower limb spasticity.

Key Exclusion Criteria:

  • The participant has any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity or the participant's overall ability to participate in the study.
  • The participant has ambulation difficulties due to any concomitant disease or disorder other than MS.
  • The participant has any known or suspected to cannabinoids (CBs) or any of the of the medicinal product (IMP).
  • The participant has a positive drug screening test, except for non-CB medications used to treat a medical condition and reported as such by the participant; the participant has a positive drug screen test for cannabis/delta-9-tetrahydrocannabinol.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Lu AG06466

    Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.

    Drug: Lu AG06466

  • Placebo comparator
    Placebo

    Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Spasticity Response

    Spasticity response defined as ≥30% increase from baseline in spasticity Numerical Rating Scale (NRS) score

    Time frame: Baseline to Week 5

  2. Change from Baseline to Week 5 in Spasticity NRS Score

    Time frame: Baseline, Week 5

07

Study locations

7 sites
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Wake Research - Clinical Research Center of Nevada
    Las Vegas, Nevada 89106, United States
  • Universitätsklinikum Düsseldorf
    Dusseldorf NRW, 40225, Germany
  • Neurostimulation Center for Movement Disorders
    Mainz, 55131, Germany
  • Center of Neurology, Hertie Institute for Clinical Brain Research
    Tubingen, 72076, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 4, 2021
StartActual
Sep 27, 2021
Primary completionActual
Jan 19, 2023
CompletionActual
Jan 31, 2023
Last update
Feb 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04990219
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 4, 2021
Start date
Sep 27, 2021
Primary completion
Jan 19, 2023
Completion
Jan 31, 2023
Last update
Feb 3, 2023

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX-1431

Start the discussion